Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medexus PharmaceuticalsTSX:MDP +1.40%52 Days Sales Outstanding is 43.77 as of Jun. 2026, which is 26% below its 10-year median of 59.06. GuruFocus rates TSX:MDP with a GF Score™ of 52/100 and a GF Value™ of C$2.08 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, Medexus Pharmaceuticals ranks better than 78.88% on this metric.
The historical rank and industry rank for Medexus Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
TSX:MDP'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.85 Med: 59.06 Max: 79.65
Current: 44.92
During the past 13 years, Medexus Pharmaceuticals's highest Days Sales Outstanding was 79.65. The lowest was 24.85. And the median was 59.06.
TSX:MDP's Days Sales Outstanding is ranked better than 78.88% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs TSX:MDP: 44.92
Medexus Pharmaceuticals's Days Sales Outstanding
declined
from Jun. 2025 (48.28) to Jun. 2026 (43.77).
Medexus Pharmaceuticals (TSX:MDP) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Medexus Pharmaceuticals Days Sales Outstanding Related Terms
Medexus Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Medexus Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals Days Sales Outstanding Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Days Sales Outstanding falls into.
Medexus Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (TSX:MDP) has a Days Sales Outstanding of 43.77 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Medexus Pharmaceuticals and its competitors. This is 26% below median its historical median of 59.06. Over the past decade, Medexus Pharmaceuticals' Days Sales Outstanding has ranged from 24.85 to 79.65. According to the industry distribution chart, Medexus Pharmaceuticals ranks #200 out of 947 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Medexus Pharmaceuticals' Days Sales Outstanding too high?
Medexus Pharmaceuticals' current Days Sales Outstanding of 43.77 is 26% below median its 10-year median of 59.06. Over the past 10 years, this metric has ranged from a low of 24.85 to a high of 79.65. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Medexus Pharmaceuticals' value of 43.77 is 39.2% below this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #200 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #200 out of 947 companies for Days Sales Outstanding. This places Medexus Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.98. Medexus Pharmaceuticals' value of 43.77 is 39.2% below this benchmark. Historically, Medexus Pharmaceuticals' own Days Sales Outstanding has ranged from 24.85 to 79.65 over the past decade. While the company's 10-year median is 59.06 vs. the industry median of 71.98, Medexus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Days Sales Outstanding of 43.77 is 39.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Days Sales Outstanding is 43.77, which is 26% below median its own 10-year median of 59.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$2.08, compared to a current price of C$5.08 — trading 144.2% above its estimated fair value. The current Days Sales Outstanding is 43.77, which is 26% below median its 10-year median of 59.06 and 39.2% below the Drug Manufacturers industry median of 71.98. Medexus Pharmaceuticals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Days Sales Outstanding is 43.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of C$5.08 is trading 144.2% above its estimated GF Value™ of C$2.08.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSX:MDP:
Days Sales Outstanding: 43.77 (26% below median its 10-year median of 59.06)
GF Value™: C$2.08 vs. price of C$5.08 (144.2% above fair value)
Industry Position: 39.2% below the Drug Manufacturers median (#200 of 947)
No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
52GF Score
Get the complete analysis for TSX:MDP
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MDP has been successfully added to your 
